20
The Society Pages
therapeutic antibody immune therapies.
If all goes well, we will have an anti-leukemia antibody that is ready for a clinical
trial,” he explained. Dr. An is professor
of molecular medicine and the Robert A.
Welch Distinguished University Chair in
Chemistry at UTHealth. He also directs
the Texas Therapeutics Institute at the
UTHealth Brown Foundation Institute of
Molecular Medicine for the Prevention of
Human Diseases.
Source: University of Texas Health press release
NIH Awards Karen-Sue
Carlson of MCW a Grant to
Study Blood Disorders
Karen-Sue Carlson,
MD, PhD, assistant
professor of medicine in hematology
and oncology at the
Medical College of
Wisconsin (MCW),
was awarded a five-year, $635,000
grant from the National Institutes of
Health’s (NIH’s) National Heart, Lung,
and Blood Institute to identify new
potential treatments for diseases that
inhibit the growth of blood cells and
diseases in which the blood cells develop abnormally. Dr. Carlson will focus
her research on abnormalities in hematopoietic stem cells and the supportive
microenvironment, as well as the role
of the protein laminin in maintaining
the bone marrow environment necessary to grow new blood cells.
Source: Medical College of Wisconsin press release
Pew Charitable Trusts
Announce Newest Class of
Pew-Stewart Scholars
The Pew Charitable Trusts and the
Alexander and Margaret Stewart Trust
recently announced the latest class of
T:7”
without a dose reduction, 50% in the REVLIMID/dexamethasone
treatment group had at least one additional dose interruption with or
without a dose reduction compared to 21% in the placebo/dexamethasone
treatment group. Most adverse reactions and Grade 3/4 adverse reactions
were more frequent in patients who received the combination of
REVLIMID/dexamethasone compared to placebo/dexamethasone.
Table 5: Adverse Reactions Reported in ≥5% of Patients and with a
≥2% Difference in Proportion of Patients Between the
REVLIMID/dexamethasone and Placebo/dexamethasone Groups
System Organ Class/ Preferred Term REVLIMID/Dex* Placebo/Dex *
(N=353)
(N=350)
n (%)
n (%)
Tables 5, 6, and 7 summarize the adverse reactions reported for
REVLIMID/dexamethasone and placebo/dexamethasone groups.
Metabolism and nutrition disorders
Anorexia
Hypokalemia
Hypocalcemia
Appetite Decreased
Dehydration
Hypomagnesemia
Investigations
Weight Decreased
Eye disorders
Blurred vision
Vascular disorders
Deep vein thrombosis%
Hypertension
Hypotension
55 (15.6)
48 (13.6)
31 (8.8)
24 (6.8)
23 (6.5)
24 (6.8)
34 (9.7)
21 (6.0)
10 (2.9)
14 (4.0)
15 (4.3)
10 (2.9)
69 (19.5)
52 (14.9)
61 (17.3)
40 (11.4)
33 (9.3)
28 (7.9)
25 (7.1)
15 (4.3)
20 (5.7)
15 (4.3)
Table 6: Grade 3/4 Adverse Reactions Reported in ≥2% Patients
and With a ≥1% Difference in Proportion of Patients Between the
REVLIMID/dexamethasone and Placebo/dexamethasone groups
System Organ Class/ Prefer